drugset / Trial / NCT07284758

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT07284758

Phase 2 Recruiting 100 enrolled C4 Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Timeline

Start
2026-02-18
Primary completion
2030-03
Completion
2030-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cemsidomide Small molecule Oral
Background Dexamethasone Small molecule Oral

Indications